NEORNAT

NEORNAT Inc. is a specialized RNA anti-cancer therapeutics developing company that discovers first-in-class targets through RNA functional research and in vitro & in vivo verification studies, and conducts clinical development with NEORAT's own RNA treatment strategies... For a long time, RNA has been attracting attention only for its role in transcribing proteins based on genomic DNA sequences, but recently, it has been reported that numerous non-coding RNAs have a pivotal roles on the transcription and translation of functional genes in cells. NEORNAT aims to become a leading company in the development of RNA therapeutics that selectively target RNA or RNA regulatory factors contributing diseases, particularly cancer, with high-level research as the source technology. The main pipelines are first-in-class RNA targets including macrophage immune-checkpoint inhibitor, oncogenic super enhancer, long non-coding RNA (lncRNAs), and DNA repair enzymes. In addition, NEORNAT discovered..

Also known as: NEORNAT Inc., NEORNAT, Co., Ltd.

Registration numbers: 636-88-01728 (W)

Primary location: Seoul Korea